About ASCP. Includes contact information. Membership resources and application Meetings, conventions, and many more educational opportunities The Consultant Pharmacist, ASCP Update, Clinical Consult, Business Quarterly, TCP Supplements, and the ASCP Product Catalog Extensive resources for the new pharmacy practicioner News and press releases from ASCP Extensive resources to help you advance your practice Up-to-date information on legislative and regulative activities affecting your practice. Includes the ASCP Advocacy Center. Discussion forums and career resources What's happening in the next year American Society of Consultant Pharmacists Research and Education Foundation
ascp.rxschool.com


CE Home | Help | Login | Register   


 Medicare Part D Drug Benefit
  Course Information Back to Catalog   

This lesson is supported by:






This course was delivered as a live teleconference on January 31, 2005.  You may not receive credit for both the live and distance lessons.  If you attended the live teleconference and would like to receive credit please click on LiveCE located under the Courses tab when you are logged in. 

Description of Course
The Centers for Medicare & Medicaid Services are expected to issue final regulations for implementation of the Medicare Part D drug benefit in mid-January. Discussion will focus on the final regulations issued by CMS for implementation of the Medicare drug benefit. The two hour presentation will cover the implementation timeline for the Medicare Part D Drug Benefit, the impact on long term care pharmacy and the nursing facility resident, and the effect on long term care pharmacy business practices in 2006.


Learning Objectives

  1. Describe the implementation timeline of the Medicare Part D drug benefit.
  2. Describe the implications of the Medicare Part D drug benefit for the Nursing Facility Resident, Skilled Nursing Facility Resident, and Assisted Living Resident.
  3. Describe Medication Therapy Management Services and formularies as regulated by the Medicare part D drug benefit.
  4. Describe the impact on business practices for pharmacy and consultant pharmacists.
  5. Describe stakeholders response to the Medicare part D drug benefit and how the profession will begin the implementation of the regulations.


Faculty
Thomas R. Clark, RPh, MS
Director, Policy and Advocacy
American Society of Consultant Pharmacists

Faculty Disclosure
Mr. Clark has nothing to disclose.


Technologies Used

Macromedia Flash Macromedia Flash
Streaming Media Streaming Media

Price: FREE!
ACPE Accreditation
ASCP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This home study web activity has been assigned a maximum of 2 credit hours (0.2 CEU) and the ACPE UPN: 203-000-05-250-H03.

Expiration Date: 01/31/2006

Release Date: 02/04/2005

 
To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.

The material presented here does not reflect the views of Pharmacy Choice, Inc., RxSchool, or the companies providing educational content. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

This lesson is supported by:







Powered By RxSchool

© Copyright 2010 RxSchool